Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in …
https://www.sanofi.com/assets/dotcom/pressreleases/2024/2024-04-23-05-00-00-2867327-en.pdf
WEB1 day ago · immunology pipeline and a testament to Sanofi’s ability to successfully accelerate and build a portfolio of next-generation transformative treatments for immune diseases • In addition to ITP, rilzabrutinib is being studied across a variety of immune-mediated diseases including asthma, chronic spontaneous urticaria, prurigo nodularis, …
DA: 38 PA: 26 MOZ Rank: 93